Merseyside Inter Agency Drug Misuse Database

January - March 2011

Knowsley DAAT

Quarter 4 2010/11

Martin Chandler and Steven Griffith

DRAFT REPORT
The final version will be available on the IAD website

www.cph.org.uk/iad

Contacts:

Martin Chandler

IAD Manager

Centre for Public Health

Faculty of Health & Applied Social Sciences

Liverpool John Moores University

2nd Floor, Henry Cotton Campus,

15-21 Webster Street, Liverpool.

L3 2ET

(0151) 231 4349

m.chandler@ljmu.ac.uk

Steven Griffith

IAD Researcher

(0151) 231 4309

S.W.Griffith@ljmu.ac.uk

www.cph.org.uk/iad

Contents

Introduction

The Inter Agency Drug Misuse Database (IAD), established by Merseyside Drug (and Alcohol) Action Teams, Merseyside Police and the Public Health Sector (now Centre for Public Health) in 1997, supports the need for local information on drug misuse. In particular the IAD aims to:

- Provide comprehensive reporting of problem drug users' (PDUs') characteristics including a range of demographics and the types of drugs used.
- Reflect levels of service and intervention activity.
- Assist in D(A)AT's (and other responsible bodies) performance management.
- Facilitate the planning and development of services and interventions for PDUs.
- Identify gaps in service provision and delivery, as well as under-served groups as specified by the National Treatment Agency and Department of Health and by the Centre for Public Health, through interrogation of available data.
- Highlight changes in levels, demographics and characteristics of drug user populations.
- Report back to both individual D(A)ATs and service providers in the form of audits and quarterly reports as well as responding to ad hoc requests.
- Provide summary reporting on an annual basis.

To enable the above the IAD collects data from as many agencies in contact with drug users as possible and is continually seeking to expand the range and scope of data providers. Data are currently collected from criminal justice services, needle and syringe programmes (both pharmacy and agency-based), the National Drug Treatment Monitoring System (NDTMS) and Connexions (young people).

Data considerations

Analysis of data depends on the provision of attributable information. Each service provider records first and last initials, date of birth and gender, for each individual they record a contact with. The combination of these details provides an identifier (attributor) for each individual (e.g.: HF07/12/1974M). This is a nationally recognised system and allows individuals to be tracked through different service providers and across time whilst retaining an acceptable degree of anonymity. The attributor is essential to avoid double counting of individuals both within and across datasets, as well as enabling us to match across datasets. The D(A)AT referred to is the D(A)AT of contact unless otherwise stated.

The IAD will *only* be reporting attributable data for each dataset. In the past, report deadlines have been missed due to data arriving too late to be cleaned and analysed in time, or more often because the data requires a great deal of cleaning and validation before analysis. These reports are useful only if they can arrive within timelines useful to D(A)ATs (ie: in time for NTA quarterly submissions). For this reason, reports will now be sent out according to a strict timetable, with each quarter's report to be sent in the first week of the third month following the close of the reporting period. Any data that is missing or non-attributable will not be included in the report.

The Centre for Public Health will continue to work closely with service providers and D(A)ATs in order to improve both the timeliness and quality of monitoring data provided to the IAD. Many service providers are turning to electronic recording of data and it is hoped this will vastly improve the quality of the data as systems improve.

ARREST REFERRAL (AR)

Quarter 4 (2010/11)

Introduction

Raw data are provided by the Drug Intervention Programme (DIP) Team based at the Centre for Public Health, Liverpool John Moores University. The data supplied are for validated contacts within specified D(A)AT areas and are aggregated to one person per D(A)AT area. Individuals may therefore appear more than once within the final dataset if they have been seen in more than one D(A)AT area, but only once for each D(A)AT area within the reporting period. Data are based on initial contact in court or custody suites representing a sub section of the full DIP dataset, further information is available from the IAD on request.

Table 1: Individuals assessed, by Gender & Age Group

Gender	n	%
Male	40	88.9
Female	5	11.1
Age Group		
Under 18	0	0.0
18-19	1	2.2
20-24	7	15.6
25-29	13	28.9
30-34	6	13.3
35-39	9	20.0
40-44	6	13.3
45+	3	6.7
Total	45	100

Table 2: Year to Date, by Gender & Age Group

	Gender				Total in Age Group	
	Male		Female			
Age Group	n	%	n	%	n	%
Under 18	0	0.0	0	0.0	0	0.0
18-19	15	7.9	0	0.0	15	7.2
20-24	36	18.9	4	21.1	40	19.1
25-29	33	17.4	4	21.1	37	17.7
30-34	27	14.2	5	26.3	32	15.3
35-39	38	20.0	5	26.3	43	20.6
40-44	25	13.2	1	5.3	26	12.4
45+	16	8.4	0	0.0	16	7.7
Total	190	100	19	100	209	100

Table 3: Reported Main Drug(s)* of Use, by Frequency of Use

Drug of Use	Daily	Weekly	Monthly
Amphetamines	0	0	0
Benzodiazepines	0	0	0
Cannabis	5	0	0
Crack	1	3	0
Cocaine	2	10	17
Ecstasy	0	0	0
Heroin	3	1	0
Methadone	1	0	0
Other	0	0	0

 2 individuals did not report a main drug of use

NB: The complexity of the drug profiles reported through arrest referral is such that we have decided the best way of reporting the data is to provide figures for the number of people reporting Daily, Weekly or Monthly use of each drug. Where "Main drug" is provided in the original data it does not always match the other substances reported as being used daily; consequently, this method of reporting should provide a more accurate picture of drug use as reported through Arrest Referral rather than simply stating the "Main Drug". However it should be noted that some people may report several drugs being used and will therefore be counted in the figures for each drug they report. For this reason totals are not provided.

NEEDLE AND SYRINGE PROGRAMMES

Quarter 4 (2010/11)

Introduction

Data are collected directly from needle and syringe programmes (NSPs). Analysis of NSP data allows performance monitoring of harm reduction services at both D(A)AT and service provider level.

AGENCY NSP

Table 4: Individuals by Gender

New Clients	n	%
Male	52	94.5
Female	3	5.5
Total	55	100
All Clients		
Male	193	96.5
Female	7	3.5
Total	200	100

Table 5: Individuals by Gender: Steroids Users Omitted

New Clients	n	%
Male	6	66.7
Female	3	33.3
Total	9	100
All Clients		
Male	32	82.1
Female	7	17.9
Total	39	100

Table 6: Individuals by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	2	3.6	5	2.5
20-24	13	23.6	40	20.0
25-29	12	21.8	49	24.5
30-34	13	23.6	35	17.5
35-39	9	16.4	35	17.5
40-44	4	7.3	25	12.5
45+	2	3.6	11	5.5
Total	55	100	200	100

Table 7: Individuals by Age Group: Steroid Users omitted

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	0	0.0	0	0.0
20-24	2	22.2	2	5.1
25-29	0	0.0	2	5.1
30-34	0	0.0	2	5.1
35-39	3	33.3	12	30.8
40-44	3	33.3	15	38.5
45+	1	11.1	6	15.4
Total	9	100	39	100

Table 8: Gender by Age Group of Individuals

Age Group	Gender			
	Male		Female	
	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	5	2.6	0	0.0
20-24	40	20.7	0	0.0
25-29	48	24.9	1	14.3
30-34	35	18.1	0	0.0
35-39	31	16.1	4	57.1
40-44	24	12.4	1	14.3
45+	10	5.2	1	14.3
Total	193	100	7	100

Table 9: Gender by Age Group: Steroid Users omitted

Age Group	Gender			
	Male		Female	
	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	0	0.0	0	0.0
20-24	2	6.3	0	0.0
25-29	1	3.1	1	14.3
30-34	2	6.3	0	0.0
35-39	8	25.0	4	57.1
40-44	14	43.8	1	14.3
45+	5	15.6	1	14.3
Total	32	100	7	100

Table 10: Year to Date, by Gender & Age Group

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	0	0.0	0	0.0	0	0.0
18-19	12	2.6	0	0.0	12	2.5
20-24	109	23.3	2	13.3	111	23.0
25-29	115	24.6	3	20.0	118	24.4
30-34	87	18.6	0	0.0	87	18.0
35-39	76	16.2	4	26.7	80	16.6
40-44	51	10.9	2	13.3	53	11.0
45+	18	3.8	4	26.7	22	4.6
Total	468	100	15	100	483	100

Table 11: Year to Date, by Gender & Age Group: Steroid Users Omitted

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	0	0.0	0	0.0	0	0.0
18-19	0	0.0	0	0.0	0	0.0
20-24	3	4.6	2	16.7	5	6.5
25-29	4	6.2	1	8.3	5	6.5
30-34	7	10.8	0	0.0	7	9.1
35-39	20	30.8	4	33.3	24	31.2
40-44	23	35.4	2	16.7	25	32.5
45+	8	12.3	3	25.0	11	14.3
Total	65	100	12	100	77	100

Table 12: Main Drug of Use for New Agency NSP Clients, by Gender

	Gender			
	Male		Female	
Drug of Use	n	%	n	%
Amphetamines	0	0.0	0	0.0
Benzodiazepines	0	0.0	0	0.0
Cocaine	0	0.0	0	0.0
Crack	0	0.0	0	0.0
Heroin	6	11.5	3	100
Methadone	0	0.0	0	0.0
Steroids	46	88.5	0	0.0
Morphine	0	0.0	0	0.0
Unknown	0	0.0	0	0.0
Total	52	100	3	100

Table 13: Main Drug of Use for All NSP Exchange Clients, by Gender

	Gender			
	Male		Female	
Drug of Use	n	%	n	%
Amphetamines	0	0.0	0	0.0
Benzodiazepines	0	0.0	0	0.0
Cocaine	1	0.5	0	0.0
Crack	0	0.0	0	0.0
Heroin	27	14.0	7	100
Methadone	1	0.5	0	0.0
Morphine	0	0.0	0	0.0
Steroids	161	83.4	0	0.0
Unknown	3	1.5	0	0.0
Total	193	100	7	100

Current Quarter; Melanotan Clients

- 0 New Male clients reported using melanotan during Q4
- 0 New Female clients reported using melanotan during Q4
- 0Male clients reported using melanotan during Q4
- 0 Female clients reported using melanotan during Q4

Table 14: Year to Date; Main Drug of Use for All NSP Exchange Clients, by Gender

	Gender			
	Male		Female	
Drug of Use	**n**	**%**	**n**	**%**
Amphetamines	0	0.0	0	0.0
Benzodiazepines	0	0.0	0	0.0
Cocaine	1	7.1	1	0.2
Crack	0	0.0	1	0.2
Heroin	10	71.4	58	12.4
Methadone	0	0.0	1	0.2
Morphine	0	0.0	0	0.0
Steroids	2	14.3	402	86.1
Unknown	1	7.1	4	0.8
Total	467	100	14	100

Year to Date; Melanotan Clients
- 0 Male clients reported using melanotan
- 0 Female clients reported using melanotan

Table 15: Main Drug of Use for Agency Syringe Exchange Clients, by Age Group

	Ampheta-mine		Cocaine		Heroin		Methadone		Steroids		Unknown	
Age Group	**n**	**%**	**n**	**%**	**n**	**%**	**n**	**%**	**n**	**%**	**n**	**%**
Under 18	0	0.00	0	0.0	0	0.0	0	0.0	0	0.0	0	0.0
18-19	0	0.00	0	0.00	0	0.00	0	0.00	5	3.1	0	0.00
20-24	0	0.00	0	0.00	2	5.9	0	0.00	38	23.6	0	0.00
25-29	0	0.00	0	0.00	2	5.9	0	0.00	47	29.2	0	0.00
30-34	0	0.00	0	0.00	2	5.9	0	0.00	33	20.5	0	0.00
35-39	0	0.00	0	0.00	11	32.4	0	0.00	23	14.3	1	33.3
40-44	0	0.00	1	100	11	32.4	1	100	10	6.2	2	66.6
45+	0	0.00	0	0.00	6	17.6	0	0.00	5	3.1	0	0.00
Total	0	0.00	1	100	**34**	**100**	1	100	**161**	**100**	**3**	**100**

* % Totals are by drug, not Age Group

PHARMACY NSPs

Table 16: Individuals by Gender

New Clients	n	%
Male	12	80.0
Female	3	20.0
Total	15	100
All Clients		
Male	22	81.5
Female	5	18.5
Total	27	100

Table 17: Individuals by Site

	Individuals	
PNSP Site	**n**	**%**
Alliance Leathers Lane Halewood	0	0.0
Rowlands West Vale Kirkby	0	0.0
Rowlands Richard Hesketh Dr Kirkby	0	0.0
Rowlands St Laurences Medical Centre	0	0.0
Newtown Chemist Kirkby	23	85.2
Halewood Health Resource Centre	4	14.8
Total	27	100

Table 18: Individuals by Age Group

	New Clients		All Clients	
Age Group	**n**	**%**	**n**	**%**
Under 18	0	0.0	0	0.0
18-19	1	6.7	1	3.7
20-24	4	26.7	5	18.5
25-29	3	20.0	3	11.1
30-34	2	13.3	2	7.4
35-39	2	13.3	7	25.9
40-44	1	6.7	5	18.5
45+	2	13.3	4	14.8
Total	15	100	27	100

Table 19: Year to Date; by Gender & Age Group

Age Group	Gender				Total in Age Group	
	Male		Female			
	n	%	n	%	n	%
Under 18	0	0.0	0	0.0	0	0.0
18-19	1	1.7	0	0.0	1	1.4
20-24	6	10.2	1	7.7	7	9.7
25-29	7	11.9	3	23.1	10	13.9
30-34	4	6.8	1	7.7	5	6.9
35-39	15	25.4	4	30.8	19	26.4
40-44	19	32.2	0	0.0	19	26.4
45+	7	11.9	4	30.8	11	15.3
Total	59	100	13	100	72	100

COMBINED PHARMACY AND AGENCY NSP

Analyses here are based on an aggregated combination of Agency and Pharmacy-based datasets for the reporting period. Data are aggregated by attributor and D(A)AT to one person per D(A)AT area.

Table 20: Individuals in Agency and Pharmacy NSP, by Gender

New Clients	n	%
Male	64	92.8
Female	5	7.2
Total	69	100
All Clients		
Male	210	95.5
Female	10	4.5
Total	220	100

Table 21: Individuals in Agency and Pharmacy NSP, by Gender: Steroid Users Omitted*

New Clients	n	%
Male	18	78.3
Female	5	21.7
Total	23	100
All Clients		
Male	51	83.6
Female	10	16.4
Total	61	100

*Only known steroid users, based on Agency NSP data and some Pharmacy NSP, have been omitted.

Table 22: Individuals in Agency and Pharmacy NSP , by Age Group

	New Clients		All Clients	
Age Group	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	3	4.3	6	2.7
20-24	17	24.6	43	19.5
25-29	15	21.7	52	23.6
30-34	15	21.7	37	16.8
35-39	10	14.5	39	17.7
40-44	5	7.2	28	12.7
45+	4	5.8	15	6.8
Total	69	100	220	100

Table 23: Individuals in Agency and Pharmacy NSP, by Age Group: Steroid Users Omitted

	New Clients		All Clients	
Age Group	n	%	n	%
Under 18	0	0.0	0	0.0
18-19	1	4.3	1	1.6
20-24	6	26.1	7	11.5
25-29	3	13.0	5	8.2
30-34	2	8.7	4	6.6
35-39	4	17.4	16	26.2
40-44	4	17.4	18	29.5
45+	3	13.0	10	16.4
Total	23	100	61	100

Table 24: Year to Date, by Gender & Age Group

	Gender				Total in Age Group	
	Male		Female			
Age Group	n	%	n	%	n	%
Under 18	0	0.0	0	0.0	0	0.0
18-19	13	2.5	0	0.0	13	2.4
20-24	112	21.8	3	11.1	115	21.3
25-29	123	23.9	6	22.2	129	23.8
30-34	89	17.3	1	3.7	90	16.6
35-39	84	16.3	6	22.2	90	16.6
40-44	67	13.0	2	7.4	69	12.8
45+	26	5.1	9	33.3	35	6.5
Total	514	100	27	100	541	100

Table 25: Combined Pharmacy and Agency NSP Total Syringes Provided

	Agency	Pharmacy	Total (Q)	Year to Date
Barrels	7,604	854	8,458	33,166

NB: We will no longer be reporting needle returns as it is not possible to accurately calculate them from the data available. Total Syringes include exchanges by non-attributable individuals.

NSP SERVICE ACTIVITY SUMMARY

Data presented here illustrate service activity across all NSP types including number of transactions, proportion of data that are attributable and a split of activity by NSP type. Individuals by NSP type are also summarised for comparative purposes.

Table 26: All NSP transactions by NSP Type

All Transactions	n	%
Kirkby CDT	223	55.1
South Knowsley CDT	102	25.2
Pharmacy NSPs	80	19.7
Total	405	100

Fig 1: NSP Service Activity; Transactions by NSP Type

Table 27: NSP Transactions, Attributable Data

All Attributable Transactions	n	%*
Kirkby CDT	223	59.9
South Knowsley CDT	100	26.9
Pharmacy NSPs	49	13.2
Total	372	100

*****Represents proportion of transactions that were attributable during the current quarter.

Table 28: PNSP Transactions and Individuals by Site

	Transactions		Individuals	
PNSP Site	**n**	**%**	**n**	**%**
Alliance Leathers Lane Halewood	0	0.0	0	0.0
Rowlands West Vale Kirkby	0	0.0	0	0.0
Rowlands Richard Hesketh Dr Kirkby	31	38.8	0	0.0
Rowlands St Laurences Medical Centre	0	0.0	0	0.0
Newtown Chemist Kirkby	45	56.2	23	85.2
Halewood Health Resource Centre	4	5	4	14.8
Total	80	100	27	100

Table 29: All NSP Individuals by NSP Type

All Clients	**n**	**%**
Kirkby CDT	138	60.8
South Knowsley CDT	62	27.3
Pharmacy NSPs	27	11.9
Total	227	100

Fig 2: NSP Service Activity; Individuals by NSP Type

National Drug Treatment Monitoring System (NDTMS)
Quarter 4 (2010/11)

Background

The NDTMS is the official method for measuring the extent and nature of structured drug treatment in England and Wales. The system is commissioned by the NTA and is operated through nine regional centres – corresponding to the nine government offices for the regions.

Data here are aggregated to one individual per D(A)AT. Individuals presenting in more than one D(A)AT within the quarter's time period will therefore be represented more than once in the original data. The D(A)AT referred to is D(A)AT of treatment.

New Clients

Figures presented here for "new" clients are calculated using the triage date. Those individuals triaged within the reporting period are taken as new clients for this report. However, it should be noted that these individuals may have been triaged, or are in contact with treatment services, before this period.

Table 30: Individuals in Contact with Treatment Services, by Gender

New Clients	n	%
Male	148	82.7
Female	31	17.3
Total	179	100
All Clients		
Male	1,039	75.7
Female	333	24.3
Total	1,372	100

Table 31: Year to Date, by Gender

New Clients	n	%
Male	494	79.4
Female	128	20.6
Total	622	100
All Clients		
Male	1,098	75.8
Female	351	24.2
Total	1,449	100

Table 32: Individuals in Contact with Treatment Services, by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	24	13.4	193	14.1
18-19	5	2.8	41	3.0
20-24	24	13.4	145	10.6
25-29	25	14.0	187	13.6
30-34	19	10.6	231	16.8
35-39	29	16.2	261	19.0
40-44	25	14.0	196	14.3
45+	28	15.6	118	8.6
Total	179	100	1,372	100

Table 33: Year to Date, Individuals in Contact with Treatment Services, by Age Group

Age Group	New Clients		All Clients	
	n	%	n	%
Under 18	83	13.3	195	13.5
18-19	30	4.8	44	3.0
20-24	97	15.6	159	11.0
25-29	98	15.8	199	13.7
30-34	86	13.8	239	16.5
35-39	104	16.7	274	18.9
40-44	70	11.3	210	14.5
45+	54	8.7	129	8.9
Total	622	100	1,449	100

Table 34: Ethnicity of Individuals in Contact with Treatment Services

Ethnicity	New Clients		All Clients	
	n	%	n	%
White British	175	97.8	1,349	98.3
White Irish	1	< 1	1	< 1
Other White	0	0.0	0	0.0
White & Black Caribbean	0	0.0	2	< 1
White & Asian	0	0.0	0	0.0
White and Black African	1	< 1	3	< 1
African	0	0.0	1	< 1
Other Black	1	< 1	3	< 1
Caribbean	0	0.0	0	0.0
Chinese	0	0.0	0	0.0
Other	1	< 1	4	< 1
Unknown	0	0.0	9	< 1
Total	179	100	1,372	100

Table 35: Individuals in Contact with Treatment Services, by Main Drug of Use

Drug of Use	New Clients		All Clients	
	n	%	n	%
Heroin	48	26.8	589	42.9
Methadone	15	8.4	51	3.7
Other Opiates	7	3.9	30	2.2
Benzodiazepines	1	< 1	6	< 1
Amphetamines	0	0.0	6	< 1
Cocaine	66	36.9	352	25.7
Crack	6	3.4	21	1.5
Hallucinogens	0	0.0	1	< 1
Ecstasy	0	0.0	6	< 1
Cannabis	32	17.9	298	21.7
Antidepressants	0	0.0	1	< 1
Mephedrone	1	< 1	1	< 1
Prescription Drugs	3	1.7	8	< 1
Other/Unknown	0	0.0	2	< 1
Total	179	100	1,372	100

COMBINED DATASETS

Quarter 4 (2010/11)

Introduction

Data presented here are drawn from a combination of datasets relating to Arrest Referrals, Probation, NSPs (Agency and Pharmacy) and NDTMS. The combined data are aggregated on attributor and D(A)AT area of intervention (except Probation, which is based on residence), to produce overall figures for numbers of individuals in contact with services reporting to the IAD. Figures presented here will not necessarily reflect the combined totals of data presented earlier as duplicate attributors are removed. These figures should not be taken as a measure of prevalence of problem drug users, but reflects the total number of problem drug users in contact with a range of agencies. Further information on the processes of data manipulation, aggregation and analysis is available from the IAD Manager.

Table 36: Total Problem Drug Users reported to the IAD, by Gender and Age Group

Gender	n	%
Male	1,225	78.3
Female	339	21.7
Age Group		
Under 18	193	12.3
18-19	47	3.0
20-24	185	11.8
25-29	238	15.2
30-34	266	17.0
35-39	289	18.5
40-44	214	13.7
45+	132	8.4
Total	1,564	100

Table 37: Year to Date, by Gender and Age Group

|	Gender					
	Male		Female		*Total in Age Group*	
Age Group	n	%	n	%	*n*	%
Under 18	128	8.0	65	17.3	193	9.8
18-19	58	3.6	5	1.3	63	3.2
20-24	244	15.3	32	8.5	276	14.0
25-29	265	16.6	58	15.5	323	16.4
30-34	260	16.3	63	16.8	323	16.4
35-39	279	17.5	62	16.5	341	17.3
40-44	233	14.6	51	13.6	284	14.4
45+	128	8.0	39	10.4	167	8.5
Total	1,595	100	375	100	1,970	100

CROSS-MATCHED DATASETS
Quarter 4 (2010/11)

Data are shown for the crossover between each type of Needle and Syringe Programme and NDTMS, separately, during the current reported quarter. For the purposes of this analysis, known steroid users were removed as they are less likely to be accessing structured drug treatment.

For methodological reasons the crossover between all three datasets will no longer be reported. Further information is available from the IAD manager if required.

NB: Numbers in brackets refer to the total reported for that service type, with steroid users omitted. These include the numbers appearing on the crossover sections. Analyses for the crossover areas are based on D(A)AT of needle and syringe programme site.

**Fig 3: Current Quarter Crossover between Agency NSP and NDTMS datasets**

AGENCY (39)   Male 20   Female 4   NDTMS (1,372)

Fig 4: Current Quarter Crossover between Pharmacy NSP and NDTMS Datasets

PHARMACY (27)   Male 18   Female 3   NDTMS (1,372)

Fig 5: Year to Date Crossover between Agency NSP and NDTMS datasets

Page 21

AGENCY (77) Male 41 Female 5 NDTMS (1,449)

Fig 6: Year to Date Crossover between Pharmacy NSP and NDTMS datasets

PHARMACY (72) Male 57 Female 7 NDTMS (1,449)